Loading...

PE anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_29F.1A12_PE_100909
Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • A_29F.1A12_PE_100909
    Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • B_29F.1A12_PE_100909
    Con A stimulated (3 days) C57BL/6 splenocytes stained with rat IgG2a isotype PE and CD3e (145-2C11) APC
Compare all formats See PE spectral data
Cat # Size Price Save
135205 50 µg ¥21,850
135206 200 µg ¥60,930
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References

(PubMed link indicates BioLegend citation)
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  2. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  3. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  4. Liu M, et al. 2022. Cells. 11: . PubMed
  5. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  6. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  7. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  8. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  9. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  10. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  11. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  12. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  13. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  14. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
  15. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  16. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  17. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  18. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  19. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  20. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  21. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  22. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  23. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  24. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  25. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  26. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  27. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  28. Lu SX, et al. 2021. Cell. . PubMed
  29. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  30. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  31. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  32. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  33. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  34. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  35. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  36. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  37. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  38. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  39. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  40. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  41. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  42. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  43. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  44. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  45. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  46. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  47. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  48. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  49. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  50. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  51. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  52. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  53. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  54. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  55. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  56. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  57. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  58. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  59. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  60. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  61. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  62. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  64. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  65. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  66. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  67. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  68. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  69. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  70. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  71. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  72. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  73. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  74. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  75. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
RRID
AB_1877231 (BioLegend Cat. No. 135205)
AB_1877231 (BioLegend Cat. No. 135206)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All PD-1 Reagents Request Custom Conjugation
Description Clone Applications
PE anti-mouse CD279 (PD-1) 29F.1A12 FC
Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block,ELISA
PerCP/Cyanine5.5 anti-mouse CD279 (PD-1) 29F.1A12 FC
APC anti-mouse CD279 (PD-1) 29F.1A12 FC
Biotin anti-mouse CD279 (PD-1) 29F.1A12 FC
FITC anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 421™ anti-mouse CD279 (PD-1) 29F.1A12 FC,SB
Brilliant Violet 605™ anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 785™ anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Dazzle™ 594 anti-mouse CD279 (PD-1) 29F.1A12 FC
Alexa Fluor® 647 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 711™ anti-mouse CD279 (PD-1) 29F.1A12 FC
GoInVivo™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Fire™ 750 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 510™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Ultra-LEAF™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block
APC/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Cyanine5 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 640 anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Red™ 718 anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 806 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 750™ anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 780 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 700 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 650™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Blue™ 574 anti-mouse CD279 (PD-1) (Flexi-Fluor™) 29F.1A12 FC
Spark PLUS B550™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Go To Top Version: 3    Revision Date: 09/11/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account